Clinical trial
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable…
NCT00076609 · PhytoCeutica, Industry · Completed
Key facts
| NCT number | NCT00076609 |
|---|---|
| Title | Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma |
| Official title | A Phase I/II Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma |
| Lead sponsor | PhytoCeutica, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma, Liver Cancer |
| Intervention type | Drug |
| Interventions | PHY906, capecitabine |
| Enrollment | 31 |
| Start date | Oct 1, 2003 |
| First posted | Jan 28, 2004 |
| Last update posted | Mar 28, 2007 |
| Countries | Taiwan, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: